Pediatric clinical trial update: Q2 2026

The second quarter of 2026 brought a dense stream of clinical trial developments with potential implications for pediatric care, spanning rare metabolic and skeletal disorders, neurology, endocrinology, gastroenterology, neuromuscular disease, and infectious disease prevention. From durable hormone control in congenital adrenal hyperplasia and sustained growth gains in skeletal dysplasias to early gene therapy signals in inherited deafness and urea cycle disorders, investigators reported findings across the development spectrum—from first-in-human and preclinical work to pivotal phase 3 readouts that could shape regulatory decisions in the back half of the year.